TY - STD TI - Panel OKs CAR T therapy for leukemia. Cancer Discov. 2017;7(9):924. ID - ref1 ER - TY - JOUR AU - Grupp, S. A. PY - 2013 DA - 2013// TI - Chimeric antigen receptor-modified T cells for acute lymphoid leukemia JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1215134 DO - 10.1056/NEJMoa1215134 ID - Grupp2013 ER - TY - JOUR AU - Gross, G. AU - Waks, T. AU - Eshhar, Z. PY - 1989 DA - 1989// TI - Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity JO - Proc Natl Acad Sci U S A VL - 86 UR - https://doi.org/10.1073/pnas.86.24.10024 DO - 10.1073/pnas.86.24.10024 ID - Gross1989 ER - TY - JOUR AU - Ahmad, Z. A. PY - 2012 DA - 2012// TI - scFv antibody: principles and clinical application JO - Clin Dev Immunol VL - 2012 UR - https://doi.org/10.1155/2012/980250 DO - 10.1155/2012/980250 ID - Ahmad2012 ER - TY - JOUR AU - Dotti, G. AU - Savoldo, B. AU - Brenner, M. PY - 2009 DA - 2009// TI - Fifteen years of gene therapy based on chimeric antigen receptors: “are we nearly there yet?” JO - Hum Gene Ther VL - 20 UR - https://doi.org/10.1089/hum.2009.142 DO - 10.1089/hum.2009.142 ID - Dotti2009 ER - TY - JOUR AU - Hombach, A. PY - 2006 DA - 2006// TI - Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor JO - J Immunol VL - 177 UR - https://doi.org/10.4049/jimmunol.177.8.5668 DO - 10.4049/jimmunol.177.8.5668 ID - Hombach2006 ER - TY - JOUR AU - Fesnak, A. D. AU - June, C. H. AU - Levine, B. L. PY - 2016 DA - 2016// TI - Engineered T cells: the promise and challenges of cancer immunotherapy JO - Nat Rev Cancer VL - 16 UR - https://doi.org/10.1038/nrc.2016.97 DO - 10.1038/nrc.2016.97 ID - Fesnak2016 ER - TY - JOUR AU - Irving, B. A. AU - Weiss, A. PY - 1991 DA - 1991// TI - The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways JO - Cell VL - 64 UR - https://doi.org/10.1016/0092-8674(91)90314-O DO - 10.1016/0092-8674(91)90314-O ID - Irving1991 ER - TY - JOUR AU - Haynes, N. M. PY - 2001 DA - 2001// TI - Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma JO - J Immunol VL - 166 UR - https://doi.org/10.4049/jimmunol.166.1.182 DO - 10.4049/jimmunol.166.1.182 ID - Haynes2001 ER - TY - JOUR AU - Brocker, T. AU - Karjalainen, K. PY - 1995 DA - 1995// TI - Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes JO - J Exp Med VL - 181 UR - https://doi.org/10.1084/jem.181.5.1653 DO - 10.1084/jem.181.5.1653 ID - Brocker1995 ER - TY - JOUR AU - Finney, H. M. PY - 1998 DA - 1998// TI - Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product JO - J Immunol VL - 161 ID - Finney1998 ER - TY - JOUR AU - Shen, C. J. PY - 2013 DA - 2013// TI - Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma JO - J Hematol Oncol VL - 6 UR - https://doi.org/10.1186/1756-8722-6-33 DO - 10.1186/1756-8722-6-33 ID - Shen2013 ER - TY - JOUR AU - Maher, J. PY - 2002 DA - 2002// TI - Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor JO - Nat Biotechnol VL - 20 UR - https://doi.org/10.1038/nbt0102-70 DO - 10.1038/nbt0102-70 ID - Maher2002 ER - TY - JOUR AU - Savoldo, B. PY - 2011 DA - 2011// TI - CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients JO - J Clin Invest VL - 121 UR - https://doi.org/10.1172/JCI46110 DO - 10.1172/JCI46110 ID - Savoldo2011 ER - TY - JOUR AU - Kofler, D. M. PY - 2011 DA - 2011// TI - CD28 costimulation impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation JO - Mol Ther VL - 19 UR - https://doi.org/10.1038/mt.2011.9 DO - 10.1038/mt.2011.9 ID - Kofler2011 ER - TY - JOUR AU - Koehler, H. PY - 2007 DA - 2007// TI - CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-2098 DO - 10.1158/0008-5472.CAN-06-2098 ID - Koehler2007 ER - TY - JOUR AU - Pule, M. A. PY - 2005 DA - 2005// TI - A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells JO - Mol Ther VL - 12 UR - https://doi.org/10.1016/j.ymthe.2005.04.016 DO - 10.1016/j.ymthe.2005.04.016 ID - Pule2005 ER - TY - JOUR AU - Hombach, A. A. PY - 2012 DA - 2012// TI - OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells JO - Oncoimmunology VL - 1 UR - https://doi.org/10.4161/onci.19855 DO - 10.4161/onci.19855 ID - Hombach2012 ER - TY - JOUR AU - Chmielewski, M. AU - Hombach, A. A. AU - Abken, H. PY - 2014 DA - 2014// TI - Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma JO - Immunol Rev VL - 257 UR - https://doi.org/10.1111/imr.12125 DO - 10.1111/imr.12125 ID - Chmielewski2014 ER - TY - JOUR AU - Chmielewski, M. AU - Abken, H. PY - 2015 DA - 2015// TI - TRUCKs: the fourth generation of CARs JO - Expert Opin Biol Ther VL - 15 UR - https://doi.org/10.1517/14712598.2015.1046430 DO - 10.1517/14712598.2015.1046430 ID - Chmielewski2015 ER - TY - JOUR AU - Lopez-Albaitero, A. PY - 2017 DA - 2017// TI - Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody JO - Oncoimmunology VL - 6 UR - https://doi.org/10.1080/2162402X.2016.1267891 DO - 10.1080/2162402X.2016.1267891 ID - Lopez-Albaitero2017 ER - TY - JOUR AU - Yu, S. PY - 2017 DA - 2017// TI - Chimeric antigen receptor T cells: a novel therapy for solid tumors JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0444-9 DO - 10.1186/s13045-017-0444-9 ID - Yu2017 ER - TY - JOUR AU - Liu, B. AU - Song, Y. AU - Liu, D. PY - 2017 DA - 2017// TI - Clinical trials of CAR-T cells in China JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0535-7 DO - 10.1186/s13045-017-0535-7 ID - Liu2017 ER - TY - JOUR AU - Hartmann, J. PY - 2017 DA - 2017// TI - Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts JO - EMBO Mol Med VL - 9 UR - https://doi.org/10.15252/emmm.201607485 DO - 10.15252/emmm.201607485 ID - Hartmann2017 ER - TY - JOUR AU - Gargett, T. AU - Brown, M. P. PY - 2014 DA - 2014// TI - The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells JO - Front Pharmacol VL - 5 UR - https://doi.org/10.3389/fphar.2014.00235 DO - 10.3389/fphar.2014.00235 ID - Gargett2014 ER - TY - JOUR AU - Diaconu, I. PY - 2017 DA - 2017// TI - Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells JO - Mol Ther VL - 25 UR - https://doi.org/10.1016/j.ymthe.2017.01.011 DO - 10.1016/j.ymthe.2017.01.011 ID - Diaconu2017 ER - TY - JOUR AU - Chen, N. PY - 2017 DA - 2017// TI - CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy JO - Oncoimmunology VL - 6 UR - https://doi.org/10.1080/2162402X.2016.1273302 DO - 10.1080/2162402X.2016.1273302 ID - Chen2017 ER - TY - JOUR AU - Ahmed, N. PY - 2015 DA - 2015// TI - Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.0225 DO - 10.1200/JCO.2014.58.0225 ID - Ahmed2015 ER - TY - JOUR AU - You, F. PY - 2016 DA - 2016// TI - Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified anti-MUC1 chimeric antigen receptor transduced T cells JO - Sci China Life Sci VL - 59 UR - https://doi.org/10.1007/s11427-016-5024-7 DO - 10.1007/s11427-016-5024-7 ID - You2016 ER - TY - JOUR AU - Brown, C. E. PY - 2015 DA - 2015// TI - Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0428 DO - 10.1158/1078-0432.CCR-15-0428 ID - Brown2015 ER - TY - JOUR AU - Katz, S. C. PY - 2015 DA - 2015// TI - Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-1421 DO - 10.1158/1078-0432.CCR-14-1421 ID - Katz2015 ER - TY - JOUR AU - Petrausch, U. PY - 2012 DA - 2012// TI - Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1) JO - BMC Cancer VL - 12 UR - https://doi.org/10.1186/1471-2407-12-615 DO - 10.1186/1471-2407-12-615 ID - Petrausch2012 ER - TY - JOUR AU - Brown, C. E. PY - 2016 DA - 2016// TI - Regression of glioblastoma after chimeric antigen receptor T-cell therapy JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1610497 DO - 10.1056/NEJMoa1610497 ID - Brown2016 ER - TY - JOUR AU - Brentjens, R. J. PY - 2011 DA - 2011// TI - Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-04-348540 DO - 10.1182/blood-2011-04-348540 ID - Brentjens2011 ER - TY - JOUR AU - Kershaw, M. H. PY - 2006 DA - 2006// TI - A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-1183 DO - 10.1158/1078-0432.CCR-06-1183 ID - Kershaw2006 ER - TY - JOUR AU - Lamers, C. H. PY - 2013 DA - 2013// TI - Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity JO - Mol Ther VL - 21 UR - https://doi.org/10.1038/mt.2013.17 DO - 10.1038/mt.2013.17 ID - Lamers2013 ER - TY - JOUR AU - Lamers, C. H. PY - 2016 DA - 2016// TI - Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells––a completed study overview JO - Biochem Soc Trans VL - 44 UR - https://doi.org/10.1042/BST20160037 DO - 10.1042/BST20160037 ID - Lamers2016 ER - TY - JOUR AU - Park, J. R. PY - 2007 DA - 2007// TI - Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma JO - Mol Ther VL - 15 UR - https://doi.org/10.1038/sj.mt.6300104 DO - 10.1038/sj.mt.6300104 ID - Park2007 ER - TY - JOUR AU - Beatty, G. L. PY - 2014 DA - 2014// TI - Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies JO - Cancer Immunol Res VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-13-0170 DO - 10.1158/2326-6066.CIR-13-0170 ID - Beatty2014 ER - TY - JOUR AU - Maus, M. V. PY - 2013 DA - 2013// TI - T cells expressing chimeric antigen receptors can cause anaphylaxis in humans JO - Cancer Immunol Res VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0006 DO - 10.1158/2326-6066.CIR-13-0006 ID - Maus2013 ER - TY - JOUR AU - Beatty, G. L. PY - 2015 DA - 2015// TI - Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer JO - J Clin Oncol VL - 33 ID - Beatty2015 ER - TY - STD TI - Feng K, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 2017. https://doi.org/10.1007/s13238-017-0440-4. UR - https://doi.org/10.1007/s13238-017-0440-4 ID - ref42 ER - TY - JOUR AU - Ahmed, N. PY - 2015 DA - 2015// TI - Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a phase I trial JO - J Immunother Cancer VL - 3 UR - https://doi.org/10.1186/2051-1426-3-S2-O11 DO - 10.1186/2051-1426-3-S2-O11 ID - Ahmed2015 ER - TY - JOUR AU - Feng, K. PY - 2016 DA - 2016// TI - Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer JO - Sci China Life Sci VL - 59 UR - https://doi.org/10.1007/s11427-016-5023-8 DO - 10.1007/s11427-016-5023-8 ID - Feng2016 ER - TY - JOUR AU - Feng, K. C. PY - 2017 DA - 2017// TI - Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-016-0378-7 DO - 10.1186/s13045-016-0378-7 ID - Feng2017 ER - TY - JOUR AU - Louis, C. U. PY - 2011 DA - 2011// TI - Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-05-354449 DO - 10.1182/blood-2011-05-354449 ID - Louis2011 ER - TY - JOUR AU - Tchou, J. PY - 2017 DA - 2017// TI - Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-17-0189 DO - 10.1158/2326-6066.CIR-17-0189 ID - Tchou2017 ER - TY - JOUR AU - Junghans, R. P. PY - 2016 DA - 2016// TI - Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response JO - Prostate VL - 76 UR - https://doi.org/10.1002/pros.23214 DO - 10.1002/pros.23214 ID - Junghans2016 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Stuelten, C. H. PY - 2005 DA - 2005// TI - Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta JO - J Cell Sci VL - 118 UR - https://doi.org/10.1242/jcs.02334 DO - 10.1242/jcs.02334 ID - Stuelten2005 ER - TY - JOUR AU - Palucka, A. K. AU - Coussens, L. M. PY - 2016 DA - 2016// TI - The basis of oncoimmunology JO - Cell VL - 164 UR - https://doi.org/10.1016/j.cell.2016.01.049 DO - 10.1016/j.cell.2016.01.049 ID - Palucka2016 ER - TY - JOUR AU - Friedl, P. AU - Alexander, S. PY - 2011 DA - 2011// TI - Cancer invasion and the microenvironment: plasticity and reciprocity JO - Cell VL - 147 UR - https://doi.org/10.1016/j.cell.2011.11.016 DO - 10.1016/j.cell.2011.11.016 ID - Friedl2011 ER - TY - JOUR AU - Newick, K. AU - Moon, E. AU - Albelda, S. M. PY - 2016 DA - 2016// TI - Chimeric antigen receptor T-cell therapy for solid tumors JO - Mol Ther Oncolytics VL - 3 UR - https://doi.org/10.1038/mto.2016.6 DO - 10.1038/mto.2016.6 ID - Newick2016 ER - TY - JOUR AU - Moon, E. K. PY - 2011 DA - 2011// TI - Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-11-0351 DO - 10.1158/1078-0432.CCR-11-0351 ID - Moon2011 ER - TY - JOUR AU - Craddock, J. A. PY - 2010 DA - 2010// TI - Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b JO - J Immunother VL - 33 UR - https://doi.org/10.1097/CJI.0b013e3181ee6675 DO - 10.1097/CJI.0b013e3181ee6675 ID - Craddock2010 ER - TY - JOUR AU - Schuberth, P. C. PY - 2013 DA - 2013// TI - Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells JO - J Transl Med VL - 11 UR - https://doi.org/10.1186/1479-5876-11-187 DO - 10.1186/1479-5876-11-187 ID - Schuberth2013 ER - TY - JOUR AU - Lo, A. PY - 2015 DA - 2015// TI - Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-3041 DO - 10.1158/0008-5472.CAN-14-3041 ID - Lo2015 ER - TY - JOUR AU - Chinnasamy, D. PY - 2010 DA - 2010// TI - Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice JO - J Clin Invest VL - 120 UR - https://doi.org/10.1172/JCI43490 DO - 10.1172/JCI43490 ID - Chinnasamy2010 ER - TY - JOUR AU - Caruana, I. PY - 2015 DA - 2015// TI - Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3833 DO - 10.1038/nm.3833 ID - Caruana2015 ER - TY - JOUR AU - Garin-Chesa, P. AU - Old, L. J. AU - Rettig, W. J. PY - 1990 DA - 1990// TI - Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers JO - Proc Natl Acad Sci U S A VL - 87 UR - https://doi.org/10.1073/pnas.87.18.7235 DO - 10.1073/pnas.87.18.7235 ID - Garin-Chesa1990 ER - TY - JOUR AU - Beyer, I. AU - van Rensburg, R. AU - Lieber, A. PY - 2013 DA - 2013// TI - Overcoming physical barriers in cancer therapy JO - Tissue Barriers VL - 1 UR - https://doi.org/10.4161/tisb.23647 DO - 10.4161/tisb.23647 ID - Beyer2013 ER - TY - JOUR AU - Beyer, I. PY - 2011 DA - 2011// TI - Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab JO - Mol Ther VL - 19 UR - https://doi.org/10.1038/mt.2010.256 DO - 10.1038/mt.2010.256 ID - Beyer2011 ER - TY - JOUR AU - Qin, L. PY - 2017 DA - 2017// TI - Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0437-8 DO - 10.1186/s13045-017-0437-8 ID - Qin2017 ER - TY - JOUR AU - Balkwill, F. R. AU - Capasso, M. AU - Hagemann, T. PY - 2012 DA - 2012// TI - The tumor microenvironment at a glance JO - J Cell Sci VL - 125 UR - https://doi.org/10.1242/jcs.116392 DO - 10.1242/jcs.116392 ID - Balkwill2012 ER - TY - JOUR AU - Khawar, I. A. AU - Kim, J. H. AU - Kuh, H. J. PY - 2015 DA - 2015// TI - Improving drug delivery to solid tumors: priming the tumor microenvironment JO - J Control Release VL - 201 UR - https://doi.org/10.1016/j.jconrel.2014.12.018 DO - 10.1016/j.jconrel.2014.12.018 ID - Khawar2015 ER - TY - JOUR AU - Kerkar, S. P. PY - 2010 DA - 2010// TI - Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-10-0735 DO - 10.1158/0008-5472.CAN-10-0735 ID - Kerkar2010 ER - TY - JOUR AU - Pegram, H. J. PY - 2012 DA - 2012// TI - Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-12-400044 DO - 10.1182/blood-2011-12-400044 ID - Pegram2012 ER - TY - JOUR AU - Avanzi, M. P. PY - 2016 DA - 2016// TI - IL-18 secreting CAR T cells enhance cell persistence, induce prolonged B cell aplasia and eradicate CD19+ tumor cells without need for prior conditioning JO - Blood VL - 128 ID - Avanzi2016 ER - TY - JOUR AU - Boice, M. PY - 2016 DA - 2016// TI - Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells JO - Cell VL - 167 UR - https://doi.org/10.1016/j.cell.2016.08.032 DO - 10.1016/j.cell.2016.08.032 ID - Boice2016 ER - TY - JOUR AU - Roybal, K. T. PY - 2016 DA - 2016// TI - Engineering T cells with customized therapeutic response programs using synthetic notch receptors JO - Cell VL - 167 UR - https://doi.org/10.1016/j.cell.2016.09.011 DO - 10.1016/j.cell.2016.09.011 ID - Roybal2016 ER - TY - JOUR AU - Roybal, K. T. AU - Lim, W. A. PY - 2017 DA - 2017// TI - Synthetic immunology: hacking immune cells to expand their therapeutic capabilities JO - Annu Rev Immunol VL - 35 UR - https://doi.org/10.1146/annurev-immunol-051116-052302 DO - 10.1146/annurev-immunol-051116-052302 ID - Roybal2017 ER - TY - JOUR AU - Dent, P. PY - 2010 DA - 2010// TI - MDA-7/IL-24 as a cancer therapeutic: from bench to bedside JO - Anti-Cancer Drugs VL - 21 UR - https://doi.org/10.1097/CAD.0b013e32833cfbe1 DO - 10.1097/CAD.0b013e32833cfbe1 ID - Dent2010 ER - TY - JOUR AU - Beatty, G. L. AU - Moon, E. K. PY - 2014 DA - 2014// TI - Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment JO - Oncoimmunology VL - 3 UR - https://doi.org/10.4161/21624011.2014.970027 DO - 10.4161/21624011.2014.970027 ID - Beatty2014 ER - TY - JOUR AU - Chevolet, I. PY - 2015 DA - 2015// TI - Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma JO - Oncoimmunology VL - 4 UR - https://doi.org/10.4161/2162402X.2014.982382 DO - 10.4161/2162402X.2014.982382 ID - Chevolet2015 ER - TY - JOUR AU - Ewing, M. M. PY - 2013 DA - 2013// TI - T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development JO - Int J Cardiol VL - 168 UR - https://doi.org/10.1016/j.ijcard.2012.12.085 DO - 10.1016/j.ijcard.2012.12.085 ID - Ewing2013 ER - TY - JOUR AU - Hegde, U. P. AU - Mukherji, B. PY - 2017 DA - 2017// TI - Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies JO - Cancer Immunol Immunother VL - 66 UR - https://doi.org/10.1007/s00262-017-2007-x DO - 10.1007/s00262-017-2007-x ID - Hegde2017 ER - TY - JOUR AU - Condomines, M. PY - 2015 DA - 2015// TI - Tumor-targeted human T cells expressing CD28-based chimeric antigen receptors circumvent CTLA-4 inhibition JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0130518 DO - 10.1371/journal.pone.0130518 ID - Condomines2015 ER - TY - JOUR AU - Prosser, M. E. PY - 2012 DA - 2012// TI - Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor JO - Mol Immunol VL - 51 UR - https://doi.org/10.1016/j.molimm.2012.03.023 DO - 10.1016/j.molimm.2012.03.023 ID - Prosser2012 ER - TY - JOUR AU - John, L. B. PY - 2013 DA - 2013// TI - Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0458 DO - 10.1158/1078-0432.CCR-13-0458 ID - John2013 ER - TY - JOUR AU - Pegram, H. J. AU - Park, J. H. AU - Brentjens, R. J. PY - 2014 DA - 2014// TI - CD28z CARs and armored CARs JO - Cancer J VL - 20 UR - https://doi.org/10.1097/PPO.0000000000000034 DO - 10.1097/PPO.0000000000000034 ID - Pegram2014 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Massague, J. PY - 2008 DA - 2008// TI - TGFbeta in cancer JO - Cell VL - 134 UR - https://doi.org/10.1016/j.cell.2008.07.001 DO - 10.1016/j.cell.2008.07.001 ID - Massague2008 ER - TY - JOUR AU - Enblad, G. AU - Karlsson, H. AU - Loskog, A. S. PY - 2015 DA - 2015// TI - CAR T-cell therapy: the role of physical barriers and immunosuppression in lymphoma JO - Hum Gene Ther VL - 26 UR - https://doi.org/10.1089/hum.2015.054 DO - 10.1089/hum.2015.054 ID - Enblad2015 ER - TY - JOUR AU - Newick, K. PY - 2016 DA - 2016// TI - Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase a localization JO - Cancer Immunol Res VL - 4 UR - https://doi.org/10.1158/2326-6066.CIR-15-0263 DO - 10.1158/2326-6066.CIR-15-0263 ID - Newick2016 ER - TY - JOUR AU - Su, Y. PY - 2008 DA - 2008// TI - Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression JO - Cancer Immunol Immunother VL - 57 UR - https://doi.org/10.1007/s00262-008-0494-5 DO - 10.1007/s00262-008-0494-5 ID - Su2008 ER - TY - JOUR AU - Foster, A. E. PY - 2008 DA - 2008// TI - Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor JO - J Immunother VL - 31 UR - https://doi.org/10.1097/CJI.0b013e318177092b DO - 10.1097/CJI.0b013e318177092b ID - Foster2008 ER - TY - JOUR AU - Sakaguchi, S. PY - 2010 DA - 2010// TI - FOXP3+ regulatory T cells in the human immune system JO - Nat Rev Immunol VL - 10 UR - https://doi.org/10.1038/nri2785 DO - 10.1038/nri2785 ID - Sakaguchi2010 ER - TY - JOUR AU - Roychoudhuri, R. AU - Eil, R. L. AU - Restifo, N. P. PY - 2015 DA - 2015// TI - The interplay of effector and regulatory T cells in cancer JO - Curr Opin Immunol VL - 33 UR - https://doi.org/10.1016/j.coi.2015.02.003 DO - 10.1016/j.coi.2015.02.003 ID - Roychoudhuri2015 ER - TY - JOUR AU - Gabrilovich, D. I. AU - Nagaraj, S. PY - 2009 DA - 2009// TI - Myeloid-derived suppressor cells as regulators of the immune system JO - Nat Rev Immunol VL - 9 UR - https://doi.org/10.1038/nri2506 DO - 10.1038/nri2506 ID - Gabrilovich2009 ER - TY - JOUR AU - Mussai, F. PY - 2015 DA - 2015// TI - Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-14-3443 DO - 10.1158/0008-5472.CAN-14-3443 ID - Mussai2015 ER - TY - JOUR AU - Ostuni, R. PY - 2015 DA - 2015// TI - Macrophages and cancer: from mechanisms to therapeutic implications JO - Trends Immunol VL - 36 UR - https://doi.org/10.1016/j.it.2015.02.004 DO - 10.1016/j.it.2015.02.004 ID - Ostuni2015 ER - TY - JOUR AU - Ruella, M. PY - 2017 DA - 2017// TI - Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-0850 DO - 10.1158/2159-8290.CD-16-0850 ID - Ruella2017 ER - TY - JOUR AU - Kloss, C. C. PY - 2013 DA - 2013// TI - Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells JO - Nat Biotechnol VL - 31 UR - https://doi.org/10.1038/nbt.2459 DO - 10.1038/nbt.2459 ID - Kloss2013 ER - TY - JOUR AU - Wilkie, S. PY - 2012 DA - 2012// TI - Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling JO - J Clin Immunol VL - 32 UR - https://doi.org/10.1007/s10875-012-9689-9 DO - 10.1007/s10875-012-9689-9 ID - Wilkie2012 ER - TY - JOUR AU - Roybal, K. T. PY - 2016 DA - 2016// TI - Precision tumor recognition by T cells with combinatorial antigen-sensing circuits JO - Cell VL - 164 UR - https://doi.org/10.1016/j.cell.2016.01.011 DO - 10.1016/j.cell.2016.01.011 ID - Roybal2016 ER - TY - JOUR AU - Grada, Z. PY - 2013 DA - 2013// TI - TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy JO - Mol Ther Nucleic Acids VL - 2 UR - https://doi.org/10.1038/mtna.2013.32 DO - 10.1038/mtna.2013.32 ID - Grada2013 ER - TY - JOUR AU - Hegde, M. PY - 2015 DA - 2015// TI - A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma JO - J Immunother Cancer VL - 3 UR - https://doi.org/10.1186/2051-1426-3-S2-O3 DO - 10.1186/2051-1426-3-S2-O3 ID - Hegde2015 ER - TY - JOUR AU - Zah, E. PY - 2016 DA - 2016// TI - T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells JO - Cancer Immunol Res VL - 4 UR - https://doi.org/10.1158/2326-6066.CIR-15-0231 DO - 10.1158/2326-6066.CIR-15-0231 ID - Zah2016 ER - TY - JOUR AU - Fedorov, V. D. AU - Themeli, M. AU - Sadelain, M. PY - 2013 DA - 2013// TI - PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses JO - Sci Transl Med VL - 5 UR - https://doi.org/10.1126/scitranslmed.3006597 DO - 10.1126/scitranslmed.3006597 ID - Fedorov2013 ER - TY - JOUR AU - Bonini, C. PY - 1997 DA - 1997// TI - HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia JO - Science VL - 276 UR - https://doi.org/10.1126/science.276.5319.1719 DO - 10.1126/science.276.5319.1719 ID - Bonini1997 ER - TY - JOUR AU - Thomis, D. C. PY - 2001 DA - 2001// TI - A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease JO - Blood VL - 97 UR - https://doi.org/10.1182/blood.V97.5.1249 DO - 10.1182/blood.V97.5.1249 ID - Thomis2001 ER - TY - STD TI - Di Stasi A, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–83. ID - ref102 ER - TY - JOUR AU - Zhou, X. PY - 2014 DA - 2014// TI - Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2014-01-551671 DO - 10.1182/blood-2014-01-551671 ID - Zhou2014 ER - TY - JOUR AU - Vogler, I. PY - 2010 DA - 2010// TI - An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy JO - Mol Ther VL - 18 UR - https://doi.org/10.1038/mt.2010.83 DO - 10.1038/mt.2010.83 ID - Vogler2010 ER - TY - JOUR AU - Wang, X. PY - 2011 DA - 2011// TI - A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-02-337360 DO - 10.1182/blood-2011-02-337360 ID - Wang2011 ER - TY - JOUR AU - Wu, C. Y. PY - 2015 DA - 2015// TI - Remote control of therapeutic T cells through a small molecule-gated chimeric receptor JO - Science VL - 350 UR - https://doi.org/10.1126/science.aab4077 DO - 10.1126/science.aab4077 ID - Wu2015 ER - TY - JOUR AU - Morsut, L. PY - 2016 DA - 2016// TI - Engineering customized cell sensing and response behaviors using synthetic notch receptors JO - Cell VL - 164 UR - https://doi.org/10.1016/j.cell.2016.01.012 DO - 10.1016/j.cell.2016.01.012 ID - Morsut2016 ER - TY - JOUR AU - Kieback, E. PY - 2008 DA - 2008// TI - A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer JO - Proc Natl Acad Sci U S A VL - 105 UR - https://doi.org/10.1073/pnas.0710198105 DO - 10.1073/pnas.0710198105 ID - Kieback2008 ER - TY - JOUR AU - Kuball, J. PY - 2007 DA - 2007// TI - Facilitating matched pairing and expression of TCR chains introduced into human T cells JO - Blood VL - 109 UR - https://doi.org/10.1182/blood-2006-05-023069 DO - 10.1182/blood-2006-05-023069 ID - Kuball2007 ER - TY - JOUR AU - Cohen, C. J. PY - 2007 DA - 2007// TI - Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-3986 DO - 10.1158/0008-5472.CAN-06-3986 ID - Cohen2007 ER - TY - JOUR AU - Provasi, E. PY - 2012 DA - 2012// TI - Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer JO - Nat Med VL - 18 UR - https://doi.org/10.1038/nm.2700 DO - 10.1038/nm.2700 ID - Provasi2012 ER - TY - JOUR AU - Porter, D. L. PY - 2011 DA - 2011// TI - Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1103849 DO - 10.1056/NEJMoa1103849 ID - Porter2011 ER - TY - JOUR AU - Jin, Z. PY - 2011 DA - 2011// TI - The hyperactive sleeping beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor JO - Gene Ther VL - 18 UR - https://doi.org/10.1038/gt.2011.40 DO - 10.1038/gt.2011.40 ID - Jin2011 ER - TY - JOUR AU - Singh, N. AU - Barrett, D. M. AU - Grupp, S. A. PY - 2014 DA - 2014// TI - Roadblocks to success for RNA CARs in solid tumors JO - Oncoimmunology VL - 3 UR - https://doi.org/10.4161/21624011.2014.962974 DO - 10.4161/21624011.2014.962974 ID - Singh2014 ER - TY - JOUR AU - Lamers, C. H. PY - 2007 DA - 2007// TI - Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo JO - Cancer Immunol Immunother VL - 56 UR - https://doi.org/10.1007/s00262-007-0330-3 DO - 10.1007/s00262-007-0330-3 ID - Lamers2007 ER - TY - JOUR AU - Lamers, C. H. PY - 2011 DA - 2011// TI - Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-07-294520 DO - 10.1182/blood-2010-07-294520 ID - Lamers2011 ER - TY - JOUR AU - Lamers, C. H. PY - 2006 DA - 2006// TI - Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.05.9964 DO - 10.1200/JCO.2006.05.9964 ID - Lamers2006 ER - TY - JOUR AU - Abate-Daga, D. PY - 2014 DA - 2014// TI - A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer JO - Hum Gene Ther VL - 25 UR - https://doi.org/10.1089/hum.2013.209 DO - 10.1089/hum.2013.209 ID - Abate-Daga2014 ER - TY - JOUR AU - Morgan, R. A. PY - 2010 DA - 2010// TI - Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 JO - Mol Ther VL - 18 UR - https://doi.org/10.1038/mt.2010.24 DO - 10.1038/mt.2010.24 ID - Morgan2010 ER - TY - JOUR AU - Morgan, R. A. PY - 2012 DA - 2012// TI - Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma JO - Hum Gene Ther VL - 23 UR - https://doi.org/10.1089/hum.2012.041 DO - 10.1089/hum.2012.041 ID - Morgan2012 ER - TY - JOUR AU - Saied, A. PY - 2014 DA - 2014// TI - Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases JO - Cancer Gene Ther VL - 21 UR - https://doi.org/10.1038/cgt.2014.50 DO - 10.1038/cgt.2014.50 ID - Saied2014 ER - TY - JOUR AU - Katz, S. C. PY - 2016 DA - 2016// TI - Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery JO - Cancer Gene Ther VL - 23 UR - https://doi.org/10.1038/cgt.2016.14 DO - 10.1038/cgt.2016.14 ID - Katz2016 ER - TY - JOUR AU - Golubovskaya, V. PY - 2017 DA - 2017// TI - CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth JO - Cancers (Basel) VL - 9 UR - https://doi.org/10.3390/cancers9100139 DO - 10.3390/cancers9100139 ID - Golubovskaya2017 ER - TY - JOUR AU - Pule, M. A. PY - 2008 DA - 2008// TI - Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma JO - Nat Med VL - 14 UR - https://doi.org/10.1038/nm.1882 DO - 10.1038/nm.1882 ID - Pule2008 ER - TY - JOUR AU - Heczey, A. PY - 2014 DA - 2014// TI - Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2013-11-541235 DO - 10.1182/blood-2013-11-541235 ID - Heczey2014 ER - TY - JOUR AU - Tanaka, M. PY - 2017 DA - 2017// TI - Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-2138 DO - 10.1158/1078-0432.CCR-16-2138 ID - Tanaka2017 ER - TY - JOUR AU - Stroncek, D. F. PY - 2017 DA - 2017// TI - Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells JO - J Transl Med VL - 15 UR - https://doi.org/10.1186/s12967-017-1160-5 DO - 10.1186/s12967-017-1160-5 ID - Stroncek2017 ER - TY - JOUR AU - Zuccolotto, G. PY - 2014 DA - 2014// TI - PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0109427 DO - 10.1371/journal.pone.0109427 ID - Zuccolotto2014 ER - TY - JOUR AU - Gohil, S. H. PY - 2017 DA - 2017// TI - An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors JO - Oncoimmunology VL - 6 UR - https://doi.org/10.1080/2162402X.2017.1326437 DO - 10.1080/2162402X.2017.1326437 ID - Gohil2017 ER - TY - JOUR AU - Koneru, M. PY - 2015 DA - 2015// TI - A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer JO - J Transl Med VL - 13 UR - https://doi.org/10.1186/s12967-015-0460-x DO - 10.1186/s12967-015-0460-x ID - Koneru2015 ER -